$0.29
+0.01 (+4.18%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GTBP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 7.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological MalignanciesNCT03214666results2022-11-10GTB-3550 Dosing SummaryNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE drug product, GTB-3650. | Drug: GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II | High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Systemic Mastocytosis, Mast Cell Leukemia | 12 | 2021-08-02actual | 2022-11-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19